Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein

about

Oncocalyxone A functions as an anti-glycation agent in vitro Magnetic nanosystem for cancer therapy using oncocalyxone a, an antitomour secondary metabolite isolated from a Brazilian plant.Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

P2860

Q28545770-B3501174-07A6-497B-A851-FBB2F54874E2 Q37225130-55CD24F8-5966-4F30-B297-954D0994487E Q51313041-FF8E7F9D-E1B9-4B19-B7A9-521C8363913D

P2860

Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein

Item

http://www.wikidata.org/entity/Q36790211

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Oncocalyxone A inhibits human ...... ing to GP Ibalpha glycoprotein

@ast

Oncocalyxone A inhibits human ...... ing to GP Ibalpha glycoprotein

@en

type

Item

label

Oncocalyxone A inhibits human ...... ing to GP Ibalpha glycoprotein

@ast

Oncocalyxone A inhibits human ...... ing to GP Ibalpha glycoprotein

@en

prefLabel

Oncocalyxone A inhibits human ...... ing to GP Ibalpha glycoprotein

@ast

Oncocalyxone A inhibits human ...... ing to GP Ibalpha glycoprotein

@en

P1476

Oncocalyxone A inhibits human ...... ing to GP Ibalpha glycoprotein

@en

P2093

A M Chudzinski-Tavassi

http://www.w3.org/2001/XMLSchema#string

C M de Sousa

http://www.w3.org/2001/XMLSchema#string

J S Ventura

http://www.w3.org/2001/XMLSchema#string

M A D Ferreira

http://www.w3.org/2001/XMLSchema#string

M Schattner

http://www.w3.org/2001/XMLSchema#string

O D L Pessoa

http://www.w3.org/2001/XMLSchema#string

T L G de Lemos

http://www.w3.org/2001/XMLSchema#string

P2860

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Anthracene derivatives from Auxemma oncocalyx.

New constituents and antiplatelet aggregation and anti-HIV principles of Artemisia capillaris.

NO-independent regulatory site on soluble guanylate cyclase.

Cyclic nucleotides and phosphodiesterases in platelets.

P304

1216-1224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJP.2008.199

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

154

http://www.w3.org/2001/XMLSchema#string

P50

Nilberto Robson Falcão do Nascimento

P577

2008-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5335130

http://www.w3.org/2001/XMLSchema#string

P698

18516074

http://www.w3.org/2001/XMLSchema#string

P932

2483390

http://www.w3.org/2001/XMLSchema#string

Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein

about

P2860

P2860

Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932